AbbVie (ABBV) Maintains Immunology Dominance as Analysts Play Down Competitive Threat to Skyrizi’s Market Share from J&J’s Tremfya
AbbVie Inc. (NYSE:ABBV) is one of the best stocks for the next decade. On Dec. 12, Morgan Stanley raised the company’s price target for AbbVie to $269 from $261 with an Overweight rating on the stock. Early on December 10, HSBC upgraded AbbVie to Buy from Hold with a price target of $265, up from…